Research Topics
Genomes and Genes | John T SchillerSummaryAffiliation: National Institutes of Health Country: USA Publications
| Collaborators
|
Detail Information
Publications
Cutaneous squamous cell carcinoma: a smoking gun but still no suspectsJohn T Schiller
Laboratory of Cellular Oncology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
J Invest Dermatol 131:1595-6. 2011..Their findings show that it is very unlikely that any currently known virus is commonly responsible for the maintenance of this cancer...- Current understanding of the mechanism of HPV infectionJohn T Schiller
Laboratory of Cellular Oncology, National Cancer Institute, Bethesda, MD 20892, USA
Gynecol Oncol 118:S12-7. 2010.... - Vaccines to prevent infections by oncovirusesJohn T Schiller
Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA
Annu Rev Microbiol 64:23-41. 2010..Efforts to develop KSHV vaccines have been more limited... - In vivo mechanisms of vaccine-induced protection against HPV infectionPatricia M Day
Laboratory of Cellular Oncology, National Cancer Institute National Institutes of Health, Bethesda, MD 20892, USA
Cell Host Microbe 8:260-70. 2010..Regardless of the concentration, L2 vaccine-induced antibodies allow BM association but prevent association with the cell surface. Thus, we have revealed distinct mechanisms of vaccine-induced inhibition of virus infection in vivo... - Effect of Pap smear collection and carrageenan on cervicovaginal human papillomavirus-16 infection in a rhesus macaque modelJeffrey N Roberts
Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
J Natl Cancer Inst 103:737-43. 2011..Therefore, we determined whether a cytology specimen collection procedure (Pap smear), which disrupts the epithelium by design, renders the cervix more susceptible to HPV infection in a primate model... - Determinants of seropositivity among HPV-16/18 DNA positive young womenCarolina Porras
Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA
BMC Infect Dis 10:238. 2010..We evaluated determinants of seropositivity among 646 women infected with HPV-16 and/or HPV-18... - The initial steps leading to papillomavirus infection occur on the basement membrane prior to cell surface bindingRhonda C Kines
Laboratory of Cellular Oncology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
Proc Natl Acad Sci U S A 106:20458-63. 2009.... - Neutralization of human papillomavirus with monoclonal antibodies reveals different mechanisms of inhibitionPatricia M Day
Laboratory of Cellular Oncology, Center for Cancer Research, National Institutes of Health, Bethesda, MD 20892, USA
J Virol 81:8784-92. 2007..We conclude that neutralizing antibodies can inhibit HPV infection by multiple distinct mechanisms, and understanding these mechanisms can add insight to the HPV entry processes... - Human papillomavirus infection with multiple types: pattern of coinfection and risk of cervical diseaseAnil K Chaturvedi
Infections and Immunoepidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, 6120 Executive Blvd, EPS 7072 Rockville, MD 20852, USA
J Infect Dis 203:910-20. 2011..We investigated coinfection patterns for 25 human papillomavirus (HPV) types and assessed the risk conferred by multiple HPV types toward cervical disease... - Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccineAimee R Kreimer
Infections and Immunoepidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, 6120 Executive Blvd, EPS 7084, Rockville, MD 20852, USA
J Natl Cancer Inst 103:1444-51. 2011..Three-dose regimens for human papillomavirus (HPV) vaccines are expensive and difficult to complete, especially in settings where the need for cervical cancer prevention is greatest... - Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18Diana V Pastrana
Laboratory of Cellular Oncology, National Cancer Institute, Bethesda, MD 20892-4263, USA
Virology 321:205-16. 2004..The SEAP pseudovirus-based neutralization assay should be a practical method for quantifying potentially protective antibody responses in HPV natural history and prophylactic vaccine studies... - Maturation of papillomavirus capsidsChristopher B Buck
Laboratory of Cellular Oncology, Building 37, Room 4106, 9000 Rockville Pike, Bethesda, MD 20892-4263, USA
J Virol 79:2839-46. 2005..Despite their obvious morphological differences, mature and immature capsids are similarly neutralizable by various L1- and L2-specific antibodies... - Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2Diana V Pastrana
Laboratory of Cellular Oncology, National Cancer Institute, Bethesda, MD 20892 4263, USA
Virology 337:365-72. 2005..BPV1 L2 was exceptionally effective at inducing cross-neutralizing antibodies to these shared epitopes... - Human alpha-defensins block papillomavirus infectionChristopher B Buck
Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute/NIH, Bethesda, MD 20892-4263, USA
Proc Natl Acad Sci U S A 103:1516-21. 2006.... - Mechanisms of human papillomavirus type 16 neutralization by l2 cross-neutralizing and l1 type-specific antibodiesPatricia M Day
Laboratory of Cellular Oncology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
J Virol 82:4638-46. 2008..These findings suggest a dynamic model of virion-cell surface interactions that has implications for both evolution of viral serotypes and the efficacy of current and future HPV vaccines... - Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine TrialAimee R Kreimer
Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
Lancet Oncol 12:862-70. 2011..Human papillomavirus (HPV) 16 and 18 infections cause most cases of anal cancer. We assessed efficacy of an AS04-adjuvanted HPV 16 and HPV 18 vaccine against anal infection with HPV 16, HPV 18, or both (HPV 16/18)... - Epidemiological study of anti-HPV16/18 seropositivity and subsequent risk of HPV16 and -18 infectionsMahboobeh Safaeian
Division of Cancer Epidemiology and Genetics, Infections and Immunoepidemiology Branch, National Cancer Institute, National Institutes of Health, 6120 Executive Blvd, Ste 550, Rockville, MD 20852, USA
J Natl Cancer Inst 102:1653-62. 2010..Infection with human papillomavirus (HPV) 16 or HPV18 elicits an antibody response, but whether the elicited antibodies protect women against subsequent infection by a homologous HPV type compared with seronegative women is unknown... - Role of heparan sulfate in attachment to and infection of the murine female genital tract by human papillomavirusKatherine M Johnson
Laboratory of Cellular Oncology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
J Virol 83:2067-74. 2009..We speculate that cutaneous HPVs, such as HPV5, and genital mucosal HPVs, such as HPV16 and -31, may have evolved to recognize different forms of HSPGs to enable them to preferentially infect keratinocytes at different anatomical sites... - Papillomavirus virus-like particles induce cytokines characteristic of innate immune responses in plasmacytoid dendritic cellsPetra Lenz
Laboratory of Cellular Oncology, National Cancer Institute, National Institutes of Health, Bethesda, USA
Eur J Immunol 35:1548-56. 2005..Finally, CpG-activated pDC, but not pDC exposed to HPV16 VLP, activated lymphocytes to secrete IL-10 and low levels of IFN-gamma. Together these findings suggest a possible immunogenic effect of pDC in the setting of VLP vaccination... - Carrageenan is a potent inhibitor of papillomavirus infectionChristopher B Buck
Laboratory of Cellular Oncology, National Cancer Institute, Bethesda, Maryland, USA
PLoS Pathog 2:e69. 2006..Some of these products block HPV infectivity in vitro, even when diluted a million-fold. Clinical trials are needed to determine whether carrageenan-based products are effective as topical microbicides against genital HPVs... - Targeting the vaginal mucosa with human papillomavirus pseudovirion vaccines delivering simian immunodeficiency virus DNAShari N Gordon
Animal Models and Retroviral Vaccines Section, National Institutes of Health, Bethesda, MD 20892, USA
J Immunol 188:714-23. 2012.... - Generation of HPV pseudovirions using transfection and their use in neutralization assaysChristopher B Buck
Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
Methods Mol Med 119:445-62. 2005..Antibody-mediated PsV neutralization is detected by a reduction in SEAP activity. The neutralization assay has similar analytic sensitivity to, and higher specificity than, a standard VLP-based enzyme-linked immunosorbent assay (ELISA)... - Seroprevalence and correlates of human papillomavirus 16/18 seropositivity among young women in Costa RicaSarah Coseo
Infections and Immunoepidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, 6120 Executive Blvd, EPS, Room 7079, Rockville, MD 20852, USA
Sex Transm Dis 37:706-14. 2010..We investigated HPV16 and 18 seroepidemiology among young, unvaccinated women aged between 18 and 25... - Arrangement of L2 within the papillomavirus capsidChristopher B Buck
Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892 5624, USA
J Virol 82:5190-7. 2008..This structural information should facilitate investigation of L2 function during the assembly and entry phases of the papillomavirus life cycle... - In vivo longitudinal imaging of experimental human papillomavirus infection in mice with a multicolor fluorescence mini-endoscopy systemMakoto Mitsunaga
Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892, USA
Cancer Prev Res (Phila) 4:767-73. 2011..This method offers the ability to monitor experimental virus infections before and after intervention, thereby accelerating the development of appropriate prevention and therapy... - Cleavage of the papillomavirus minor capsid protein, L2, at a furin consensus site is necessary for infectionRebecca M Richards
Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
Proc Natl Acad Sci U S A 103:1522-7. 2006..However, to our knowledge, furin has not been previously implicated in the viral entry process. This step is potentially a target for PV inhibition... - Establishment of papillomavirus infection is enhanced by promyelocytic leukemia protein (PML) expressionPatricia M Day
Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
Proc Natl Acad Sci U S A 101:14252-7. 2004..The results identify a role for PML in the enhancement of viral infectivity in the early part of the life cycle. We propose a model in which L2 chaperones the viral genome to ND10 to efficiently initiate viral transcription... - Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenanJeffrey N Roberts
Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 4263, USA
Nat Med 13:857-61. 2007..In contrast, carrageenan, a polysaccharide present in some vaginal lubricants, prevented infection even in the presence of N-9, suggesting that carrageenan might serve as an effective topical HPV microbicide... - Human papillomavirus infection and the primary and secondary prevention of cervical cancerDouglas R Lowy
Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
Cancer 113:1980-93. 2008..The manner in which vaccination and screening programs are integrated will need to be considered carefully so that they are efficient in reducing the overall incidence of cervical cancer... - Heparan sulfate-independent cell binding and infection with furin-precleaved papillomavirus capsidsPatricia M Day
Laboratory of Cellular Oncology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
J Virol 82:12565-8. 2008..We conclude that the primary function of HSPG binding is to enable cell surface furin cleavage of L2 and that binding to a distinct cell surface receptor(s) is a subsequent step of papillomavirus infection... - Induction of autoantibodies to CCR5 in macaques and subsequent effects upon challenge with an R5-tropic simian/human immunodeficiency virusBryce Chackerian
Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
J Virol 78:4037-47. 2004.... - Prophylactic human papillomavirus vaccinesDouglas R Lowy
Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
J Clin Invest 116:1167-73. 2006..Unresolved issues include the most critical groups to vaccinate and when the vaccine's cost may be low enough for widespread implementation in the developing world, where 80% of cervical cancer occurs... - Risk of miscarriage with bivalent vaccine against human papillomavirus (HPV) types 16 and 18: pooled analysis of two randomised controlled trialsSholom Wacholder
Division of Cancer Epidemiology and Genetics, National Cancer Institute, 6120 Executive Blvd, Rockville, MD 20852, USA
BMJ 340:c712. 2010..To assess whether vaccination against human papillomavirus (HPV) increases the risk of miscarriage... - New associations of human papillomavirus, Simian virus 40, and Epstein-Barr virus with human cancerMay Wong
Biological Carcinogenesis Branch, National Cancer Institute, Bethesda, MD 20892, USA
J Natl Cancer Inst 94:1832-6. 2002 - Interaction of papillomavirus virus-like particles with human myeloid antigen-presenting cellsPetra Lenz
Laboratory of Cellular Oncology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-4040, USA
Clin Immunol 106:231-7. 2003..Our results indicate that VLPs target multiple cells of the immune system, which helps to account for VLPs being so effective in priming humoral and cellular immune responses even in the absence of adjuvant... - Combined prophylactic and therapeutic cancer vaccine: enhancing CTL responses to HPV16 E2 using a chimeric VLP in HLA-A2 miceJiahua Qian
Vaccine Branch, NCI, National Naval Medical Center, Bldg 8, Bethesda, MD 20892, USA
Int J Cancer 118:3022-9. 2006.... - The role of furin in papillomavirus infectionPatricia M Day
Laboratory of Cellular Oncology, National Cancer Institute, NIH, Bethesda, MD 20892, USA
Future Microbiol 4:1255-62. 2009..This work also has implications for further advances in papillomavirus vaccine development... - Human papillomavirus serology and the risk of esophageal and gastric cancers: results from a cohort in a high-risk region in ChinaFarin Kamangar
Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA
Int J Cancer 119:579-84. 2006..4). For HPV 73, these figures were 1.3 (0.6-2.5), 1.2 (0.6-2.3) and 0.9 (0.4-2.1). The results of this study do not support a major role for HPV 16, HPV 18 and HPV 73 in the etiology of esophageal and gastric cancers in Linxian, China... - Efficient intracellular assembly of papillomaviral vectorsChristopher B Buck
Laboratory of Cellular Oncology, National Cancer Institute, Bethesda, Maryland 20892-4263, USA
J Virol 78:751-7. 2004..The results suggest that the intracellular assembly of papillomavirus structural proteins around heterologous reporter plasmids is surprisingly promiscuous and may be driven primarily by a size discrimination mechanism... - Delivering on the promise: HPV vaccines and cervical cancerJohn T Schiller
National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
Nat Rev Microbiol 2:343-7. 2004 - An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial resultsJohn T Schiller
Laboratory of Cellular Oncology, National Cancer Institute, Bethesda, MD, USA
Vaccine 26:K53-61. 2008..The results of these studies have led to the approval of Gardasil and Cervarix by national regulatory agencies in a number of countries... - Papillomaviruses infect cells via a clathrin-dependent pathwayPatricia M Day
Laboratory of Cellular Oncology, Division of Basic Sciences, National Cancer Institute, National Institutes of Health, Building 36, Room 1D-32, Bethesda, MD 20892, USA
Virology 307:1-11. 2003..Surprisingly, the kinetics of internalization were unusually slow for this mechanism, with the t(1/2) of entry of BPV-1 being approximately 4 h versus 5-15 min for a typical ligand... - Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trialAllan Hildesheim
Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, USA
JAMA 298:743-53. 2007..Viruslike particle human papillomavirus (HPV) vaccines were designed to prevent HPV infection and development of cervical precancers and cancer. Women with oncogenic HPV infections might consider vaccination as therapy... - Prospects for cervical cancer prevention by human papillomavirus vaccinationJohn T Schiller
Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA
Cancer Res 66:10229-32. 2006..These include duration of protection, degree of cross-protection against nonvaccine types, efficacy in men, and vaccine availability to economically disadvantaged women... - Chapter 17: Second generation HPV vaccines to prevent cervical cancerJohn T Schiller
Laboratory of Cellular Oncology, National Cancer Institute, Bethesda, MD 20892, USA
Vaccine 24:S3/147-53. 2006..Three questions need to be addressed: (1) Is there sufficient need for a second generation vaccine? (2) Are there sufficiently attractive candidates for clinical trials? (3) Is there a realistic development/commercialization path?.. - Determinants of autoantibody induction by conjugated papillomavirus virus-like particlesBryce Chackerian
Laboratory of Cellular Oncology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
J Immunol 169:6120-6. 2002.... - Reducing HPV-associated cancer globallyDouglas R Lowy
Laboratory of Cellular Oncology, National Cancer Institute, 37 Convent Drive, Bethesda, MD 20892, USA
Cancer Prev Res (Phila) 5:18-23. 2012..Second-generation HPV vaccines (active against a broader array of cervical cancer-related HPV types) could prevent an even higher proportion of cervical precancer and cancer and might permit further reductions in screening intensity...